Pharmaceuticals giant AstraZeneca has stopped investing in the UK, begun stockpiling medicines at the borders, and is duplicating some of its scientific equipment in Sweden in the run-up to Brexit, said Chairman of the Board of Directors, Leif Johansson, who spoke of his frustration of having to “act in uncertainty” when the current system works “very well”. Johansson said: “We have been working with our Swedish partners for a long time on this issue
Pharmaceuticals giant AstraZeneca has stopped investing in the UK, begun stockpiling medicines at the borders, and is duplicating some of its scientific equipment in Sweden in the run-up to Brexit, said Chairman of the Board of Directors, Leif Johansson, who spoke of his frustration of having to “act in uncertainty” when the current system works “very well”. The precautionary measures are costing the UK-based company £40m ($52.7m).